Drug Profile
Hepatic fibrosis therapy - Hawaii Biotech
Alternative Names: HeptaxLatest Information Update: 16 Mar 2009
Price :
$50
*
At a glance
- Originator Hawaii Biotech
- Class Carotenoids
- Mechanism of Action Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatic fibrosis
Most Recent Events
- 10 May 2006 Hawaii Biotech has been acquired by Avantogen
- 20 Jun 2003 Preclinical trials in Hepatic fibrosis in USA (unspecified route)